Vaximm Appoints Sébastien Wieckowski, PhD, as Chief Scientific Officer to Advance Next-Generation Oral Immunotherapy Platform
PR Newswire —
BELLEVUE, Wash., Jan. 16, 2026 /PRNewswire/ -- Vaximm AG, a subsidiary of OSR Holdings, Inc. and a pioneer in oral T-cell immunotherapies for cancer, today announced the appointment of Sébastien Wieckowski, PhD, as Chief Scientific Officer (CSO). This appointment strategically strengthens...